Markedly diminished drug resistance-inducing properties of vinflunine (20′,20′-difluoro-3′,4′-dihydrovinorelbine) relative to vinorelbine, identified in murine and human tumour cells in vivo and in vitro

被引:35
作者
Etiévant, C
Kruczynski, A
Barret, JM
Tait, AS
Kavallaris, M
Hill, BT
机构
[1] Ctr Rech Pierre Fabre, Div Cancerol Expt 1, F-81106 Castres 06, France
[2] Childrens Canc Inst Australia Med Res, Randwick, NSW 2031, Australia
关键词
vinflunine; Vinca alkaloid; multidrug resistance; in vivo/in vitro resistance selection; beta-tubulin isotypes;
D O I
10.1007/s002800100275
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Vinflunine (VFL) is a novel Vinca alkaloid with markedly superior experimental in vivo antitumour activity to its parent molecule, vinorelbine (Navelbine. NVB), against a panel of murine and human tumours. The aim of this study was to establish whether there are differences in the rate and extent of development of resistance, both in vivo and in vitro, to these two newer Vinca alkaloids under identical selection conditions. Methods: Using P388 leukaemia cells in vivo. it was evident that VFL induced drug resistance far less readily than NVB, as shown by the number of passages required to select for total resistance. Under in vitro conditions. using A549 human lung carcinoma cells, it was also clearly shown by drug sensitivity determinations that VFL was a less-potent inducer of drug resistance than NVB. Resistance resulting from either in vivo or in vitro selection was associated with a classic multidrug resistance profile. Further characterization of the drug-resistance phenotype of the most highly resistant A549 sublines showed that the level of total beta -tubulin expression appeared to be modified exclusively in the NVB-resistant cells. Conclusion: The clear demonstration that resistance to VFL developed far less readily than resistance to NVB both in vivo and in vitro may have potential clinical implications.
引用
收藏
页码:62 / 70
页数:9
相关论文
共 24 条
[1]   P-GLYCOPROTEIN MEDIATED RESISTANCE TO 5'-NOR-ANHYDRO-VINBLASTINE (NAVELBINE(R)) [J].
ADAMS, DJ ;
KNICK, VC .
INVESTIGATIONAL NEW DRUGS, 1995, 13 (01) :13-21
[2]  
[Anonymous], 1988, LAB ANIM-UK, V22, P195
[3]  
Barret J.-M., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P74
[4]  
BURKHART CA, 2000, IN PRESS BIOCH BIOPH
[5]   A MECHANISM OF CELLULAR-RESISTANCE TO DRUGS THAT INTERFERE WITH MICROTUBULE ASSEMBLY [J].
CABRAL, FR ;
BRADY, RC ;
SCHIBLER, MJ .
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1986, 466 :745-756
[6]   Mechanisms of action of and resistance to antitubulin agents: Microtubule dynamics, drug transport, and cell death [J].
Dumontet, C ;
Sikic, BI .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (03) :1061-1070
[7]   Vinflunine (20′,20′-difluoro-3′,4′-dihydrovinorelbine), a novel Vinca alkaloid, which participates in P-glycoprotein (Pgp)-mediated multidrug resistance in vivo and in vitro [J].
Etievant, C ;
Barret, JM ;
Kruczynski, A ;
Perrin, D ;
Hill, BT .
INVESTIGATIONAL NEW DRUGS, 1998, 16 (01) :3-17
[8]   Vinca alkaloids in superacidic media: A method for creating a new family of antitumor derivatives [J].
Fahy, J ;
Duflos, A ;
Ribet, JP ;
Jacquesy, JC ;
Berrier, C ;
Jouannetaud, MP ;
Zunino, F .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1997, 119 (36) :8576-8577
[9]   Altered expression of M beta 2, the class II beta-tubulin isotype, in a murine J774.2 cell line with a high level of taxol resistance [J].
Haber, M ;
Burkhart, CA ;
Regl, DL ;
Madafiglio, J ;
Norris, MD ;
Horwitz, SB .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (52) :31269-31275
[10]   Superior in vivo experimental antitumour activity of vinflunine, relative to vinorelbine, in a panel of human tumour xenografts [J].
Hill, BT ;
Fiebig, HH ;
Waud, WR ;
Poupon, MF ;
Colpaert, F ;
Kruczynski, A .
EUROPEAN JOURNAL OF CANCER, 1999, 35 (03) :512-520